Orexo search Orexo websites Home About Orexo Products Pipeline Investor Press Contact Orexo is a specialist pharmaceutical company with commercial operations in the USA and R&D in Sweden. The company develops improved drugs based on its own drug delivery technology. Orexo is responsible for the commercialization of its own product Zubsolv® for maintenance treatment of opiate addiction in the American market. Zubsolv is a new sublingual formulation of buprenorphine and naloxone, based on Orexo's expertise in sublingual formulations. The company has a portfolio consisting of two revenue-generating products approved in the USA, the EU and Japan, which are currently marketed through licensing agreements. Read more Orexo winner of this year's award for best Investor Relations Read more Presentation of Q3 report Read more FDA approves higher strengths of Zubsolv® ORX Dec 19, 2014 5:29 CET SEK 132.25 + 3.7% Press releases 2014-12-17 Orexo receives interim target compensation of GBP 5 million for Abstral® in Europe and Zubsolv® continues the positive sales trend in the USA 2014-12-12 FDA approves two higher strengths of Zubsolv® 2014-11-28 Number of shares and votes in Orexo 10/22/2014 Interim report January-September 2014 Calendar 2015-01-29 Year-end report 2014 2015-04-15 Annual General Meeting 2015 2015-04-23 Interim report Q1 2015 2015-07-10 Interim report 2015 2015-10-22 Interim report Q3 2015 © 2009 Orexo AB, Contact: info@orexo.com , 018 780 88 00, Box 303, 751 05 Uppsala, Org. No. 556500-0600, Terms , null,